Calithera Biosciences, Inc. (NASDAQ:CALA) tinted gains of +1.75% (+0.09 points) to US$5.24. The volume of 0.12 Million shares climbed down over an trading activity of 231.31 Million shares. EPS ratio determined by looking at last 12 month figures is -1.28. Over the same time span, the stock marked US$9.35 as its best level and the lowest price reached was US$3.55. The corporation has a market cap of US$189.85 Million.
Calithera Biosciences, Inc. (NASDAQ:CALA)’s earnings per share has been growing at a -21.4 percent rate over the past 5 year when average revenue increase was noted as 0 percent. The return on equity ratio or ROE stands at -31.7 percent while most common profitability ratio return on investment (ROI) was -19.8 percent. The company’s institutional ownership is monitored at 65.2 percent. The company’s net profit margin has achieved the current level of 0 percent and possesses 0 percent gross margin.
Daily Analyst Recommendations
A number of key analysts, polled by FactSet, shared their views about the current stock momentum. The forecast of 4 surveyed investment analysts covering the stock advises investors to Buy stake in the company. At present, 0 analysts call it Sell, while 0 think it is Hold. Recently, analysts have updated the overall rating to 1.2. 1 analysts recommended Overweight these shares while 0 recommended Underweight, according to FactSet data.
Echo Global Logistics, Inc. (NASDAQ:ECHO) is worth US$686.22 Million and has recently risen 0.08% to US$24.64. The latest exchange of 0.38 Million shares is below its average trading activity of 257.9 Million shares. The day began at US$24.64 but the price moved to US$24.36 at one point during the trading and finally capitulating to a session high of US$25.2. The stock tapped a 52-week high of US$36.75 while the mean 12-month price target for the shares is US$29.92.
Currently, the stock carries a price to earnings ratio of 23.95, a price to book ratio of 1.75, and a price to sales ratio of 0.28. For the past 5 years, the company’s revenue has grown 20.7%, while the company’s earnings per share has grown -24.6%. With an institutional ownership near 0%, it carries an earnings per share ratio of 1.03.
Inside Look At Analysts Reviews
Latest analyst recommendations could offer little help to investors. The stock is a Buy among 4 brokerage firms polled by Factset Research. At present, 2 analysts recommended Holding these shares while 0 recommended sell, according to FactSet data. 1 analysts call it Underweight, while 5 think it is Overweight. Recently, investment analysts covering the stock have updated the mean rating to 2.